Asset Details
Do you wish to reserve the book?
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
Do you wish to request the book?
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer
2025
Overview
BackgroundMetastatic recurrence poses a significant challenge in cancer treatment, impacting patient survival and prognosis. Understanding the biological mechanisms behind it is essential for improving treatment strategies and patient outcomes. Lung cancer, the leading cause of cancer-related deaths, is a focus of research for treatment and prognosis. This study specifically targets stage III non-small cell lung cancer (NSCLC) patients following surgery due to their high recurrence variability.MethodsTo delve into the mechanisms of metastatic recurrence in stage III NSCLC patients, we used a comprehensive experimental approach. Long-term follow-up of postoperative patients was combined with single-cell sequencing to uncover tumor microenvironment changes. In vivo and in vitro experiments, including tissue cytometry analysis, real-time PCR, western blotting, gene silencing, cell co-culture, flow cytometry, and chromatin immunoprecipitation-quantitative PCR, were conducted to investigate ALCAM-related gene regulation. Tissue samples and clinical data were collected from stage III NSCLC patients who underwent lung cancer resection between August 2018 and July 2021.ResultsAnalysis revealed distinct epithelial gene expression patterns between recurrence and non-recurrence groups, highlighting the reduced interaction between ALCAM ligand on epithelial cells and CD6 receptor on T cells. Lower ALCAM levels intensified an immunosuppressive state, halting cell cycle progression and promoting tumor proliferation and migration, linked to metastatic recurrence. The transcription factor MYB was identified as a key ALCAM regulator, shedding light on its impact on tumor advancement. Reduced ALCAM expression correlated with poorer prognosis, offering insights into NSCLC recurrence mechanisms.ConclusionsOur study underscores the pivotal role of the ALCAM-CD6 axis in metastatic recurrence of stage III NSCLC. ALCAM regulation not only influences immune-tumor cell interactions but also drives tumor cell proliferation and migration by affecting the cell cycle. This finding presents a promising target for NSCLC treatment and aids in assessing patient prognosis effectively.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
Activated-Leukocyte Cell Adhesion Molecule
/ Animals
/ Antigens, Differentiation, T-Lymphocyte - metabolism
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - immunology
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Female
/ Humans
/ Male
/ Mice
/ Neoplasm Recurrence, Local - immunology
/ Patients
/ Relapse
/ Sodium
/ Tumor Microenvironment - immunology
/ Tumors
